Journal of Genetic Engineering and Biotechnology, published by Elsevier Science Inc, is a prestigious open-access journal that stands at the forefront of research in the fields of biotechnology and genetics. Since its inception in 2011, the journal has provided a platform for cutting-edge studies that explore the complexities and innovations within genetic engineering and its applications in biotechnology. With a commendable Impact Factor and recognized as a Q2 journal in both biotechnology and genetics as per 2023 categorization, it ranks well within Scopus, evidencing its influence in the scientific community. Researchers and professionals accessing articles published in this journal benefit from timely contributions that bridge theoretical and practical aspects of genetic technologies. By fostering a collaborative environment, the Journal of Genetic Engineering and Biotechnology aims to promote advancements that drive science forward, making it an essential resource for students, academics, and industry practitioners alike. For those interested in making their mark in these rapidly evolving fields, this journal offers unparalleled access to high-quality, peer-reviewed research.

Cellular Reprogramming is a prominent academic journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of cellular biology and biotechnology. With its ISSN 2152-4971 and E-ISSN 2152-4998, this journal provides an innovative platform for researchers and professionals to share groundbreaking research findings on cellular reprogramming, stem cell biology, and regenerative medicine. Established in 2010, and actively publishing until 2024, the journal is recognized for its contributions, evidenced by its categorizations in the Q3 and Q4 quartiles across several related fields, including biotechnology and developmental biology. This peer-reviewed journal not only supports open access to scientific literature but also aims to enhance interdisciplinary collaboration among scientists. With a growing impact in the realms of biochemistry, genetics, and molecular biology, Cellular Reprogramming remains an essential resource for the dissemination of pioneering research that could shape the future of cellular therapies.

Frontiers in Genome Editing, published by FRONTIERS MEDIA SA, stands at the forefront of genomic research, specializing in the rapidly evolving realm of gene editing technologies. With an enthusiastic commitment to open access since 2020, this journal facilitates unrestricted distribution of cutting-edge research, making significant advancements in biotechnology and genetics accessible to a global audience. Located in Lausanne, Switzerland, Frontiers in Genome Editing publishes high-quality, peer-reviewed articles that contribute to the understanding and application of genome editing tools, such as CRISPR and TALEN, in various biological fields. Notably, as of 2023, the journal holds a prestigious Q1 ranking in Biotechnology and a Q2 ranking in Genetics, underscoring its importance and influence within these disciplines. With robust Scopus rankings, including a notable percentile placement, Frontiers in Genome Editing is an invaluable resource for researchers, professionals, and students dedicated to the promising future of genomic innovation.

Molecular Cell, published by Cell Press, is a leading journal in the fields of cell biology and molecular biology. Established in 1997, this prestigious journal boasts a significant impact within the scientific community, evidenced by its impressive 2023 Scopus rankings, placing it in the top 2% of its field (Rank #10/410 in Molecular Biology, Rank #12/285 in Cell Biology). With a focus on cutting-edge research that bridges the gap between molecular genetics and cellular function, Molecular Cell serves as an essential platform for the dissemination of vital findings and innovative methodologies. Although it follows a traditional publishing model without Open Access options, its rigorous peer-review process and high standards ensure that articles published within these pages are of the utmost quality, making it an invaluable resource for researchers, professionals, and students alike seeking to stay at the forefront of scientific discovery. The journal's address is 50 Hampshire St, Floor 5, Cambridge, MA 02139, United States, reinforcing its commitment to fostering scientific excellence and collaboration.

Nature Plants is a premier journal dedicated to the dynamic and interdisciplinary field of plant science, published by NATURE PORTFOLIO in the United Kingdom. With an impressive impact factor placing it in the top tier of scholarly journals—ranking Q1 in Plant Science for 2023—this journal sets a high standard for research dissemination. Nature Plants has maintained a remarkable Scopus Rank of 5 out of 516 in the Agricultural and Biological Sciences category, reflecting its pivotal role in advancing knowledge in the field. The journal aims to provide a platform for groundbreaking research that addresses key challenges in plant biology, ecology, and agriculture, thereby fostering a deeper understanding of plant science's contribution to global sustainability. Although primarily non-open access, it offers exclusive insights and robust discussions, making it an indispensable resource for researchers, professionals, and students eager to explore the latest advancements and innovations in plant science.

aBIOTECH, published by SPRINGERNATURE, is a premier academic journal dedicated to advancing the fields of biotechnology, agronomy, and molecular biology. With an impressive ISSN of 2096-6326 and E-ISSN 2662-1738, this journal has established itself as a vital resource for researchers and professionals aiming to publish high-quality, impactful studies. Based in Singapore, aBIOTECH has achieved remarkable recognition, boasting a Q1 ranking in multiple categories including Agronomy and Crop Science, Biochemistry, and Genetics in the 2023 Scopus rankings. Its solid position in the 90th percentile for Biochemistry and Genetics reinforces its significance within the global scientific community. The journal covers a broad spectrum of topics relevant to both basic and applied research, facilitating a shared dialogue amongst scientists and encouraging collaborative progress in innovative biotechnological applications. The open-access nature of the journal ensures that cutting-edge research is freely available, fostering a global exchange of ideas that is critical to the advancement of science today.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

Cells, published by MDPI in Switzerland, is a leading open-access journal that has been disseminating groundbreaking research in the fields of Biochemistry, Genetics, and Molecular Biology since its inception in 2011. With an impressive E-ISSN of 2073-4409, the journal boasts a strong impact factor and ranks in the 84th percentile for Scopus ratings, underscoring its significance in advancing scientific knowledge. As a Q1-ranked journal in both 2023 and 2020, it serves as a premier platform for researchers, professionals, and students eager to explore innovative findings and methodologies. By providing unrestricted access to high-quality research, Cells plays a pivotal role in facilitating collaboration and inspiration within the global scientific community, making it an indispensable resource for anyone interested in cutting-edge discoveries in cellular biology.

Molecular Therapy Nucleic Acids is a premier open-access journal published by CELL PRESS, dedicated to advancing the field of molecular medicine through the innovative application of nucleic acid-based therapies. Since its inception in 2012, this journal has become an essential resource for researchers and professionals in drug discovery and molecular medicine, reflected in its status as a Q1 journal in both categories for 2023. With a notable impact factor and high rankings in Scopus, including #8 out of 157 in Drug Discovery and #16 out of 178 in Molecular Medicine, it serves to disseminate groundbreaking research and foster collaborations among scientists worldwide. The journal's comprehensive scope encompasses a wide variety of topics, including gene therapy, RNA interference, and CRISPR technology, ensuring that it remains at the forefront of scientific excellence. With open access availability, Molecular Therapy Nucleic Acids actively promotes the widespread dissemination of knowledge, making its crucial insights accessible to students, researchers, and industry professionals alike.